Medical/Pharmaceuticals
Akeso Reports Full-Year 2025 Financial Results
HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business. Commercial Operations Enter a New Phase of Growth In 2025, Akeso achieved record ...
2026-03-27 11:54
6167
Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million
CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia"), a commercial-stage biopharmaceutical company dedicated t...
2026-03-26 22:08
4818
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
Rapid Advancement Across Core R&D Pipeline * The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has been approved in the US. CS2009 demonstrates an excellent...
2026-03-26 21:32
9047
HealYou Built a Mental Health Platform for the Millions of Asians Who Would Never Use One
Asia is rewriting mental health — and the West may not be ready for what comes
next
TAIPEI and NEW YORK, March 26, 2026 /PRNewswire/ -- In America, Chinese
Communities Are Quietly Rewriting the Rules of Mental Health
2026-03-26 21:00
3627
Neurophet Signs MOU with ALZ-NET to Facilitate Imaging Monitoring Infrastructure for Alzheimer's Disease Therapies
* Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key solutions * Collaboration expected to leverage Neurophet AQUA, Neurophet SCALE PET and Neurophet AQUA AD Plus SEOUL, South Korea, March 26, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Ja...
2026-03-26 21:00
6121
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
Key Highlights: * Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with23% i...
2026-03-26 20:53
4900
C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China
CHENGDU, China and JANESVILLE, Wis., March 26, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, today announced the execution of aMaster Radioisotope Supply Agreement with SHINE Technologies, LLC (Janesville, Wisconsin, USA), establishing a long-term, ...
2026-03-26 20:53
3905
Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards
* Reinforcing long-term commitment to embedding sustainability across operations and partnerships * Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide INCHEON, South Korea, March 26, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a ...
2026-03-26 20:00
3552
Peijia Medical Announces 2025 Annual Results
SUZHOU, China, March 26, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the year ended December 31, 2025 on March 25, 2026. During th...
2026-03-26 20:00
5350
Innovent Announces 2025 Annual Results and Business Updates
From China Leadership to Global Premier: Revenue Surpasses RMB 10 Billion, Entering the Era of Profitability and Globalization SAN FRANCISCO and SUZHOU, China, March 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develop...
2026-03-26 18:00
5859
Lasermach by Wingderm® Receives FDA Clearance for All Three Wavelengths
BEIJING, March 26, 2026 /PRNewswire/ -- Wingderm®, a manufacturer of medical aesthetic devices, announces that its Lasermach system has received expanded clearance from the U.S. Food and Drug Administration (FDA). With this latest clearance, Lasermach now achieves FDA clearance across all three w...
2026-03-26 18:00
2490
GC Biopharma Receives Marketing Authorization for Varicella Vaccine 'BARYCELA Inj.' in Guatemala
- First regulatory clearance in Latin America marks a strategic milestone for regional market expansion - World's first antibiotic-free manufacturing process ensures superior safety profile YONGIN, South Korea, March 26, 2026 /PRNewswire/ -- GC Biopharma(006280.KS), a leading provider of biophar...
2026-03-26 14:23
3219
Hengrui Pharma Announces Strong 2025 Annual Results
SHANGHAI, March 25, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13% year-on-year to RMB 31.63 billion, and net profit attribut...
2026-03-26 08:52
4215
Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics
SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a lar...
2026-03-25 21:01
4069
Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics
- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the...
2026-03-25 20:00
3372
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company
BEIJING, March 25, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics ...
2026-03-25 20:00
4441
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. Th...
2026-03-25 18:22
4392
HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering
Listing milestone positions HanchorBio to strengthen institutional visibility, advance itsFBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases TAIPEI, SHANGHAI and SAN FRANCISCO, March 25, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a globa...
2026-03-25 18:00
3317
VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial
* Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 * A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment * Fully biological transplant eliminates need for immunosuppres...
2026-03-25 17:11
3383
BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States
BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing SUZHOU, China, March 25, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (SSE: 688166, "BrightGene" or "the Company") today announced positive topline results f...
2026-03-25 14:32
3093
Week's Top Stories
Most Reposted
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
[Picked up by 321 media titles]
2026-04-09 13:00
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
[Picked up by 312 media titles]
2026-04-09 09:00Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 308 media titles]
2026-04-06 10:00
Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
UTP Advances Across Key Disciplines in QS World University Rankings By Subject 2026 - Petroleum Engineering Among World's Top 10
[Picked up by 300 media titles]
2026-04-06 16:46
Most Read
NYSE Content Update: Starfish Space Adds Over $100 Million in Funding to Boost Growth
2026-04-07 21:06
6958
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
2026-04-09 13:00
6858
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
2026-04-09 09:00
6330